The ubiquitin proteasome pathway was discovered in the 1980s to be a central component
of the cellular protein-degradation machinery with essential functions in homeostasis, which …

The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and
SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma …

PURPOSE Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous
outcomes, and approximately 60% of them are at intermediate-risk according to the Revised …

Background Bortezomib, thalidomide, and dexamethasone (VTd) plus autologous stem-cell
transplantation is standard treatment in Europe for transplant-eligible patients with newly …

Background Ixazomib is an oral proteasome inhibitor that is currently being studied for the
treatment of multiple myeloma. Methods In this double-blind, placebo-controlled, phase 3 …

Purpose The clinical outcome of multiple myeloma (MM) is heterogeneous. A simple and
reliable tool is needed to stratify patients with MM. We combined the International Staging …

Abstract The International Myeloma Working Group consensus updates the definition for
high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities …

PURPOSE Assessing measurable residual disease (MRD) has become standard with many
tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain …

Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow,
leading to bone destruction and marrow failure. This manuscript discusses the management …

Proteasome inhibitors are one of the most important classes of agents to have emerged for
the treatment of multiple myeloma in the past two decades, and now form one of the …